Skip to main content

Advertisement

Table 1 Association between TNFAIP8 expression and clinicopathological characteristics of NSCLC patients

From: TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway

Variable All patients TNFAIP8 expression P
High (%) Low (%)
(n = 196) (n = 106) (n = 90)
Smoking
 Never 93 53 (50) 40 (44) 0.438
 Ever 103 53 (50) 50 (56)
Gender
 Male 129 68 (64) 61 (68) 0.594
 Female 67 38 (36) 29 (32)
Age (years)
  < 60 129 71 (67) 58 (64) 0.709
  ≥ 60 67 35 (33) 32 (36)
Differentiation
 Well 18 12 (11) 6 (7) 0.263
 Moderate 87 42 (40) 45 (50)
 Poor 91 52 (49) 39 (43)
Histological cell type
 Adenocarcinoma 122 70 (66) 52 (58) 0.235
 Squamous cell carcinoma 74 36 (34) 38 (42)
pStage
 I 93 43 (40.5) 50 (56) 0.022*
 II 40 20 (19) 20 (22)
 III 63 43 (40.5) 20 (22)
pT classification
 T1 51 20 (19) 31 (34) 0.034*
 T2 129 75 (71) 54 (60)
 T3/4 16 11 (10) 5 (6)
Lymph node metastasis 0.005*
 Present 82 54 (51) 28 (31)  
 Absent 114 52 (49) 62 (69)  
Adjuvant therapy
 Yes 121 62 (58) 59 (66) 0.311
 No 75 44 (42) 31 (34)
  1. Abbreviations: NSCLC non-small cell lung cancer, pTNM stage tumor, node, metastasis (pathological stage), pT pathological T stage, n number of patients. Ever: smoking at any time from the beginning of life. P value: the difference of clinicopathological characteristics between the TNFAIP8 high expression group and low expression group. *P < 0.05 was considered statistically significant